Type 2 hereditary angioedema treated with acute exacerbation with icatibant: A case report
10.4168/aard.2021.9.3.180
- Author:
Yu-Kyoung HWANG
1
;
Kyeong Min AN
;
Yong Hyun KIM
;
Sae-Hoon KIM
;
Yoon-Seok CHANG
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
- Publication Type:CASE REPORT
- From:Allergy, Asthma & Respiratory Disease
2021;9(3):180-183
- CountryRepublic of Korea
- Language:English
-
Abstract:
Hereditary angioedema (HAE) is a rare autosomal dominant disorder caused by genetic deficiency or decreased function of C1-esterase inhibitor. It is characterized by swelling of subcutaneous and submucosal tissues of the extremities, gastrointestinal tract, and upper airways which can be life-threatening. Thus, early recognition and treatment of the disease are important. Short- and longterm prophylaxes are used to decrease the severity and frequency of attacks. Icatibant is a selective bradykinin B2-receptor antagonist, earlier treatment of acute attacks and hospital admission. The authors present a case of 47-year-old woman who was diagnosed with type II HAE, danazol as a long term. Her symptoms improved dramatically after drug treatment. The unpredictability and recurrence of HAE attacks could have a negative impact on social life and quality of life. This case shows that timely and proper treatment could improve quality of life and reduce morbidity and mortality. (
